Your browser doesn't support javascript.
Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines.
Cao, Yunlong; Yisimayi, Ayijiang; Bai, Yali; Huang, Weijin; Li, Xiaofeng; Zhang, Zhiying; Yuan, Tianjiao; An, Ran; Wang, Jing; Xiao, Tianhe; Du, Shuo; Ma, Wenping; Song, Liyang; Li, Yongzheng; Li, Xiang; Song, Weiliang; Wu, Jiajing; Liu, Shuo; Li, Xuemei; Zhang, Yonghong; Su, Bin; Guo, Xianghua; Wei, Yangyang; Gao, Chuanping; Zhang, Nana; Zhang, Yifei; Dou, Yang; Xu, Xiaoyu; Shi, Rui; Lu, Bai; Jin, Ronghua; Ma, Yingmin; Qin, Chengfeng; Wang, Youchun; Feng, Yingmei; Xiao, Junyu; Xie, Xiaoliang Sunney.
  • Cao Y; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China. yunlongcao@pku.edu.cn.
  • Yisimayi A; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China. yunlongcao@pku.edu.cn.
  • Bai Y; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China.
  • Huang W; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.
  • Li X; School of Life Sciences, Peking University, Beijing, China.
  • Zhang Z; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China.
  • Yuan T; Joint Graduate Program of Peking-Tsinghua-NIBS, School of Life Sciences, Tsinghua University, Beijing, China.
  • An R; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.
  • Wang J; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.
  • Xiao T; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China.
  • Du S; School of Life Sciences, Peking University, Beijing, China.
  • Ma W; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China.
  • Song L; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.
  • Li Y; School of Life Sciences, Peking University, Beijing, China.
  • Li X; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China.
  • Song W; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.
  • Wu J; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China.
  • Liu S; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.
  • Li X; School of Life Sciences, Peking University, Beijing, China.
  • Zhang Y; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China.
  • Su B; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.
  • Guo X; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
  • Wei Y; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China.
  • Gao C; School of Life Sciences, Peking University, Beijing, China.
  • Zhang N; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China.
  • Zhang Y; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.
  • Dou Y; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
  • Xu X; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China.
  • Shi R; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.
  • Lu B; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
  • Jin R; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China.
  • Ma Y; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.
  • Qin C; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China.
  • Wang Y; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.
  • Feng Y; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
  • Xiao J; Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, China.
  • Xie XS; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China.
Cell Res ; 31(7): 732-741, 2021 07.
Article in English | MEDLINE | ID: covidwho-1237995
ABSTRACT
SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding domain (RBD) and N-terminal domain (NTD). Here we report the humoral immune response to circulating SARS-CoV-2 variants, such as 501Y.V2 (B.1.351), of the plasma and neutralizing antibodies (NAbs) elicited by CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) and natural infection. Among 86 potent NAbs identified by high-throughput single-cell VDJ sequencing of peripheral blood mononuclear cells from vaccinees and convalescents, near half anti-RBD NAbs showed major neutralization reductions against the K417N/E484K/N501Y mutation combination, with E484K being the dominant cause. VH3-53/VH3-66 recurrent antibodies respond differently to RBD variants, and K417N compromises the majority of neutralizing activity through reduced polar contacts with complementarity determining regions. In contrast, the 242-244 deletion (242-244Δ) would abolish most neutralization activity of anti-NTD NAbs by interrupting the conformation of NTD antigenic supersite, indicating a much less diversity of anti-NTD NAbs than anti-RBD NAbs. Plasma of convalescents and CoronaVac vaccinees displayed comparable neutralization reductions against pseudo- and authentic 501Y.V2 variants, mainly caused by E484K/N501Y and 242-244Δ, with the effects being additive. Importantly, RBD-subunit vaccinees exhibit markedly higher tolerance to 501Y.V2 than convalescents, since the elicited anti-RBD NAbs display a high diversity and are unaffected by NTD mutations. Moreover, an extended gap between the third and second doses of ZF2001 leads to better neutralizing activity and tolerance to 501Y.V2 than the standard three-dose administration. Together, these results suggest that the deployment of RBD-vaccines, through a third-dose boost, may be ideal for combating SARS-CoV-2 variants when necessary, especially for those carrying mutations that disrupt the NTD supersite.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Inactivated / Antibodies, Neutralizing / Immunity, Humoral / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Cell Res Year: 2021 Document Type: Article Affiliation country: S41422-021-00514-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Inactivated / Antibodies, Neutralizing / Immunity, Humoral / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Cell Res Year: 2021 Document Type: Article Affiliation country: S41422-021-00514-9